|Mr. Christian S. Schade||Chairman & CEO||N/A||N/A||1961|
|Dr. Oren Gilad Ph.D.||Co-Founder, Pres & Director||N/A||N/A||1968|
|Mr. Scott M. Coiante||Sr. VP, CFO & Sec.||N/A||N/A||1967|
|Dr. Gregory A. Korbel Ph.D.||Sr. VP & COO||N/A||N/A||1976|
|Dr. Dansu Li Ph.D.||Head of Technology||N/A||N/A||N/A|
|Dr. Lars B. Abrahmsen Ph.D.||Sr. VP & Chief Scientific Officer||N/A||N/A||1957|
|Dr. Rifat Pamukcu M.D.||Chief Medical Advisor & Director||N/A||N/A||1958|
|Mr. Hank Breslin||Head of Medicinal Chemistry||N/A||N/A||N/A|
|Dr. Michel Afargan Ph.D.||Head of Pharmacology Devel.||N/A||N/A||N/A|
|Dr. Eyal C. Attar M.D.||Sr. VP & Chief Medical Officer||N/A||N/A||1971|
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.